None listed
Conditions
Brief summary
This study looks at the role of exercise in improving the quality of life in prostate cancer patients commencing treatment with the drug Lucrin. Who is it for? You can join this study if you are a man with prostate cancer which has not spread to distant sites (metastases) and you are about to begin therapy with the hormonal treatment Lucrin. Trial details: Participants will be divided into two groups. One group will take part in progressive supervised resistance & aerobic exercises (e.g. upper and lower body resistance-based exercise using weight machines as well as aerobic exercise including walking, jogging, cycling and rowing) twice weekly (60 minutes session) for 12 weeks. The second group will receive usual care only for 12 weeks and then will take part in the 12 week exercise program. Quality of life will be assessed using the European Organization for Research and Treatment of Cancer Core Questionnaire (EORTC QLQ-C30). Physical and muscle function, body composition and psychological distress will also be assessed.
Interventions
Exercise: progressive supervised resistance exercises
(e.g. upper and lower body resistance based
exercise using weight machines) and aerobic exercise (e.g. walking, jogging, cycling, rowing etc.) twice weekly (60 minutes session) for 12 weeks. These sessions will be undertaken in small groups of participants (up to 6) and will be supervised by an Accredited Exercise Physiologist. Participants will continue their usual care for prostate cancer including treatment with the drug Lucrin for the dur
Exercise: progressive supervised resistance exercises (e.g. upper and lower body resistance based exercise using weight machines) and aerobic exercise (e.g. walking, jogging, cycling, rowing etc.) twice weekly (60 minutes session) for 12 weeks. These sessions will be undertaken in small groups of participants (up to 6) and will be supervised by an Accredited Exercise Physiologist. Participants will continue their usual care for prostate cancer including treatment with the drug Lucrin for the duration of the intervention.
Sponsors
Edith Cowan University
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used)
Eligibility
Sex/Gender
Male
Age
0 to No maximum
Healthy volunteers
No
Inclusion criteria
Prostate cancer patients initiating therapy with Lucrin and anticipate remaining so for the duration of the study, consent from physician and ability to undertake upper and lower body exercises.
Exclusion criteria
(1) bone metastatic disease, (2) musculoskeletal, cardiovascular, or neurological disorders that could inhibit participants from exercising, and/or (3) inability to undertake upper and lower limb exercise.
Outcome results
None listed